|
Title
|
|
|
|
ALK-inhibitors in NSCLC : a tabulated review of randomised phase III trials
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Three inhibitors ALK-inhibitors have been assessed in six randomised phase III trials in patients with advanced anaplastic lymphoma kinase (ALK) positive Non Small-Cell Lung Cancer (NSCLC). Patient and tumour characteristics, efficacy, and safety results are summarised in Tables 1, 2, and 3, respectively. Progression-free survival was the primary endpoint in all trials. In first-line, alectinib was superior to crizotonib, and both crizotinib and ceritinib were superior to pemetrexed plus platinum. Crizotinib and ceritinib were superior to pemetrexed or docetaxel in previously treated patients. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Belgian journal of medical oncology. - Amsterdam, 2007, currens
| |
|
Publication
|
|
|
|
Amsterdam
:
2018
| |
|
ISSN
|
|
|
|
1784-7141
| |
|
Volume/pages
|
|
|
|
12
:6
(2018)
, p. 275-278
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|